Trials / Terminated
TerminatedNCT00554385
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
The Long-term Safety and Tolerability of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 283 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-089 | Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-08-01
- First posted
- 2007-11-06
- Last updated
- 2011-08-23
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00554385. Inclusion in this directory is not an endorsement.